In summary, we have presented in vivo evidence that Dox plus IL-12 induces CD8+T cell–specific NKG2D induction, which facilitates the accumulation of NKG2D-expressing CD8+T cells in tumor sites. The gene discussed is CD8A; the disease is neoplasm.